As of March 31, 2026, Dr. Martens Plc carries a market capitalization of 703.08M, placing it among publicly traded companies globally. Its enterprise value stands at 947.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 703.08M |
| Enterprise Value | 947.00M |
Dr. Martens Plc's next confirmed earnings release is scheduled for November 26, 2026.
| Earnings Date | 11/26/2026 |
As of March 31, 2026, Dr. Martens Plc has 956.58M shares outstanding.
| Shares Outstanding | 956.58M |
These figures are as of March 31, 2026.
| PB Ratio | 1.70 |
| P/TBV Ratio | 6.75 |
As of March 31, 2026, Dr. Martens Plc maintains a current ratio of 2.61, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.61 |
| Quick Ratio | 1.13 |
| Debt / Equity | 108.85 |
These figures cover the twelve months ended March 31, 2026.
| Employee Count | 2,362.50 |
As of the close on August 26, 2026, Dr. Martens Plc's stock has declined approximately 12.15% over the past 52 weeks. The 50-day moving average sits at 0.90, while the 200-day moving average is 0.84.
| 52-Week Price Change | -12.15% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 0.84 |
As of March 31, 2026, Dr. Martens Plc holds 206.28M in cash and equivalents against 450.20M in total debt, resulting in a net debt position of 79.40M. Total book value stands at 413.59M, with working capital of 294.26M providing operational flexibility.
| Cash & Cash Equivalents | 206.28M |
| Total Debt | 450.20M |
| Net Debt | 79.40M |
| Equity (Book Value) | 413.59M |
| Book Value Per Share | 0.43 |
| Working Capital | 294.26M |
Already premium?